Fushi Copperweld Stockholders Approve Merger and 4 Stocks Riding 52-Week Highs
Fushi Copperweld (NASDAQ:FSIN) has reported that Fushi Copperweld stockholders voted at a special meeting of stockholders to approve the merger dated June 28th among the company, Green Dynasty Limited, Green Dynasty Acquisition, and Green Dynasty Holdings Limited, through which Merger Sub will merge with and into the firm, while the company continues as the surviving corporation as a wholly-owned subsidiary of Green Dynasty. Shares closed up 1.07 percent on the day at $9.46, having been traded in a 52-week range of $5.72 to $9.39.
Life Technologies (NASDAQ:LIFE) said that DNA Link has placed an order to buy 10 Ion Proton Sequencers, which are being shipped immediately. Shares closed up 1.67 percent on the day at $51.25, and have traded in a 52-week range of $37.97 to $51.47.
Are you worried about the Fiscal Cliff? Click here to get our Gold & Silver Premium Newsletter OVER 50% OFF now!
Maximus (NYSE:MMS) shares rose in early trading following Citigroup’s initiating research coverage of its stock with a Buy. In a note to investors Tuesday morning, Citi analyst James Naklicki said that Maximus might double its earnings over the next three years, and remarked that the firm may benefit as states continue moving fee-for-service Medicaid programs over to managed care. Naklicki also said that the reforms from the Affordable Care Act will create new growth opportunities for Maximus. Naklicki placed a $75 price target on the shares, which closed up 1.95 percent on the day at $64.32, having been traded in a 52-week range of $39.87 to $64.01.
Newell Rubbermaid (NYSE:NWL) reports the expansion of its Shanghai office, as the firm continues to drive its Growth Game Plan into action, commenting that, “We are adding space to accommodate a growing team with new capabilities, supported by a larger investment in the brands within our portfolio that have the ability to win bigger in this priority market. For a number of years, our Tools and Fine Writing businesses have led the way in China with solid growth, and our Commercial Products and Baby segments are also making good progress. We are now in a position to begin building our go-to-market system at scale in China, utilizing Shanghai as a key hub.” Shares closed down 1.48 percent on the day at $21.92, having been traded in a 52-week range of $14.64 to $22.25.
Thoratec Corp. (NASDAQ:THOR) announced that it has received approval from Japan’s Ministry of Health, Labour and Welfare to market HeartMate II as a Bridge-to-Transplantation therapy for patients with advanced heart failure. Thoratec and Nipro expect a commercial introduction of HeartMate II toward the end of the first quarter of 2013, subsequent to centers being trained and reimbursement in place. The opening intro will target about 15 hospitals. Shares closed up 1.84 percent on the day at $39.23, and have been traded in a 52-week range of $28.70 to $38.76.